Compare Alliant Energy Corporation (LNT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs TG Therapeutics Inc — how do they compare? Alliant Energy Corporation trades at $70.15 (market cap $17.78B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Alliant Energy Corporation is far larger — about 2.3× TG Therapeutics Inc's market cap, and Alliant Energy Corporation pays a 3.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LNT | TGTX | |
|---|---|---|
Market Cap | $17.78B | $7.64B |
Sector | Utilities | Health |
52-Week High | $78.03 | $59.06 |
52-Week Low | $63.62 | $26.94 |
Enterprise Value | $29.88B | $7.84B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $70.25, up 2.98% today, with a bearish technical signal but strong fundamentals including a P/E of 21.7 and net income margin of 18.45%. Recent Q2 2026 earnings of $0.65 per share missed some estimates but beat others, with revenue growth supported by data center demand. The stock is near support at $68, with analyst consensus bullish and a $77.67 price target.
Outlook is positive due to consistent earnings beats, dividend yield, and institutional interest, but risks include high debt levels and competitive pressures. Investors may find value in its stable cash flow and growth in utility demand, though technical weakness suggests cautious entry near support levels.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
